Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain (2016)
- Authors:
- USP affiliated authors: LAURETTI, GABRIELA ROCHA - FMRP ; COELHO, EDUARDO BARBOSA - FMRP ; LANCHOTE, VERA LUCIA - FCFRP
- Unidades: FMRP; FCFRP
- DOI: 10.1111/fcp.12168
- Subjects: ANALGÉSICOS; CITOCROMO P-450; ESTEROIDES
- Keywords: Clearance; CYP2B6; CYP3A; Fraction unbound; Tramadol
- Language: Inglês
- Imprenta:
- Publisher place: West Sussex
- Date published: 2016
- Source:
- Título do periódico: Fundamental and Clinical Pharmacology
- ISSN: 0767-3981
- Volume/Número/Paginação/Ano: v. 30, n. 2, p. 153-161, 2016
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
MORAES, Natália V. de et al. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundamental and Clinical Pharmacology, v. 30, n. 2, p. 153-161, 2016Tradução . . Disponível em: https://doi.org/10.1111/fcp.12168. Acesso em: 19 abr. 2024. -
APA
Moraes, N. V. de, Lauretti, G. R., Coelho, E. B., Godoy, A. L. P. C., Neves, D. V., & Lanchote, V. L. (2016). Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundamental and Clinical Pharmacology, 30( 2), 153-161. doi:10.1111/fcp.12168 -
NLM
Moraes NV de, Lauretti GR, Coelho EB, Godoy ALPC, Neves DV, Lanchote VL. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain [Internet]. Fundamental and Clinical Pharmacology. 2016 ; 30( 2): 153-161.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1111/fcp.12168 -
Vancouver
Moraes NV de, Lauretti GR, Coelho EB, Godoy ALPC, Neves DV, Lanchote VL. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain [Internet]. Fundamental and Clinical Pharmacology. 2016 ; 30( 2): 153-161.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1111/fcp.12168 - Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers
- The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries
- Enantioselective pharmacokinetics of lercanidipine in healthy volunteers
- Influence of lercanidipine in the kinetic sisposition of fluvastatin enantiomers in healthy volunteers
- Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: application to pharmacokinetics
- Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry
- Stereoselective analysis of metoprolol and its metabolites inrat plasma with application to oxidative metabolism
- Effects of type 2 diabetes mellitus in patients on treatment with glibenclamide and metformin on carvedilol enantiomers metabolism
- Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics
- In vivo activity of CYP2D6 and enantioselective tramadol clearance in patients with neuropathic pain
Informações sobre o DOI: 10.1111/fcp.12168 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
